Introduction Introduction
Many health care providers believe that women who initiate long-acting reversible contraceptives (LARC) discontinue the method because of side effects too soon for the method to be economical. The purpose of this quality improvement project was to implement and evaluate an evidence-based telephone triage nursing guideline for management of side effects of LARC with an ultimate goal of reducing the number of early discontinuations.
Process
A telephone triage guideline was adapted from the Contraceptive Choice Project's Clinician Call Back System, supplemented with evidence-based resources, and approved by clinicians at 2 community women's health and midwifery offices. Baseline retrospective data were collected on all women over the age of 18 who had LARC inserted at the 2 sites in the year prior to guideline implementation and in the 3 months after implementation. Rates of LARC removal at or before 3 months postinsertion, before and after guideline implementation, were evaluated.
Outcomes
Approximately 1 in 5 women called for help managing LARC side effects. Of the callers, 3 of 32 (9.4%) women receiving standard care discontinued their LARC prior to 3 months, whereas 0 of 24 women who were triaged using the guideline discontinued their LARC prior to 3 months (P = .12). Cramping, bleeding, and malposition or expulsion were the most common concerns and reasons for discontinuation.
Discussion
Fewer women than anticipated called to report side effects, and even fewer chose to discontinue their LARC early. There were fewer discontinuations with guideline use, but this was not a statistically significant difference. Most women did not discontinue their LARC early for any reason, including side effects.
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Introduction
Long-acting reversible contraceptives (LARC) are safe, highly effective methods for pregnancy prevention that are cost effective if used for an extended duration. Many healthcare providers believe that women who initiate LARC do not tolerate the common side effects and choose to remove them too soon for them to be economical. The purpose of this pilot study was to develop, implement, and evaluate an evidence-based telephone triage nursing guideline to manage side effects of LARC to reduce the number of LARC users who discontinue their method early.
Methods
Baseline retrospective data was collected on a convenience sample of all women over age 18 who had LARC inserted in the prior year at two community women's health and midwifery offices. The guideline was then implemented and data collected for three months post-insertion on a convenience sample of all women over 18 who had LARC inserted after guideline implementation. Chi-square testing and Kaplan-Meier survival analysis were used to evaluate the efficacy of the guideline on rates of LARC removal at or before 3 months post-insertion.
Results
In both cohorts, approximately 1 in 5 women called for help managing side effects. Of the women who called, 9.4% of women receiving standard care discontinued their LARC prior to 3 months, while zero women who were triaged using the guideline discontinued their LARC prior to 3 months (p = 0.12).
Discussion
Fewer women called to report side effects than anticipated, and even fewer chose to discontinue their LARC early. The small numbers of women calling and discontinuing lowered statistical power, but there was a trend toward fewer early discontinuations with use of the telephone triage guideline compared to use of non-standardized management strategies. • LARC are an efficacious and cost-effective option for women wishing to avoid pregnancy for an extended duration.
• Very few women discontinue their LARC methods early for any reason.
• Contrary to popular provider perception, most women continue their LARC beyond 3 months, when side effects are most troublesome.
• Use of a guideline for managing the adverse effects of LARC may decrease the rate of early discontinuation of the devices.
Introduction & Background
Long-acting, reversible contraceptives (LARC) are a popular topic due to their proven efficacy at preventing unplanned pregnancy. LARC include both levonorgestrel intrauterine devices (IUDs) and copper IUDs as well as etonorgestrel subdermal implants (SDIs). A single LARC can be used continuously for up to 3-12 years and are more than 99% effective with both perfect and typical use. Once inserted, they are effective almost immediately and continue to work until expiration without any further effort by the user. 1 At the time of insertion, LARC methods are more expensive than other contraceptives, but if used for an extended duration, their average cost is comparable to or less than the other methods. 2 Although LARC are recommended by several major medical organizations as first-line contraceptives for all women wishing to avoid pregnancy, 3, 4, 5 LARC remain underutilized in the United States. While low LARC usage is multifactorial, part of the problem is provider ambivalence toward LARC. This is due to the perception that many women discontinue their LARC due to side effects too early for the method to be a costeffective choice. 6 Early removal due to side effects, especially cramping and bleeding, is documented in the literature, 7, 8, 9, 10, 11 although the definition of "early removal" is not standardized. However, no study has evaluated the methods for managing LARC side effects with the goal of minimizing discontinuation due to LARC side effects. The purposes of this study included evaluation of the characteristics of women utilizing LARC methods, their complaints and reasons for early discontinuation, and whether rates of early discontinuation improved after implementation of a standardized, evidence-based telephone triage guideline for management of LARC side effects.
The Interaction Model of Client-Health Behavior was used to design this study.
Central concepts of the model include client singularity, client-professional interaction, and health outcomes. 12 Client singularity was utilized to identify the pertinent demographics and individual variables that might impact the outcomes of interest, as well as factor in the individual variables outside of provider control that must be considered when applying conclusions. Client-professional interaction served as the basis for using a guideline to assist nurses in managing the side effects experienced by the LARC user.
Health outcomes were the measurable results of the client health behavior; in this study, the primary outcome was whether the women removed their LARC prior to 3 months' use.
Methods
This pilot study utilized a two cohort, time-series design with analysis of retrospective electronic medical record data from LARC users before and after guideline implementation. The study was conducted at two institutionally-affiliated women's health and midwifery clinics in an urban setting. This study received exempt status from the St John Fisher College IRB prior to initiation of the study procedures.
A convenience sample of LARC users was identified from an insertion log kept in the regular course of practice at the two clinics. Because data was collected retrospectively and de-identified prior to analysis, consent was not required, and so data was collected from all adult women (age ≥18 years) who had LARC inserted at the clinic Descriptive statistics for callers can be seen in Table 2 . Of these women, there were no statistically significant demographic or descriptive differences between Cohort 1 and Cohort 2, although power was limited due to small sample size. As shown in Table 3 , the most common complaints of callers were bleeding (55.6%) and cramping (32.1%). Only 23 women (7.8%) had their LARC removed during follow-up, and only 11 (3.9%) discontinued their LARC within 3 months of insertion. The reasons for early discontinuation are listed in Table 4 . Of note, 5 of the 23 women discontinued their LARC due to expulsion or malposition (included in the "other" category) and zero discontinued due to cramping.
Two-tailed Chi-square (with T-tests for the continuous variable, age) was used to determine whether variables were associated with the primary outcome (whether LARC users in each cohort had discontinued their LARC prior to 3 months post-insertion).
Results of these tests for all LARC users and for the Callers subset can be viewed on Table 5 . No statistically significant association was found between any variables and discontinuation except for cohort designation (p=0.047) among all LARC users. Among the callers subset, no statistically significant association was found between any variables and discontinuation. Kaplan-Meier survival analysis was used to analyze the pattern of discontinuation between cohorts among the caller subset, as seen in Figure 1 . A trend toward less discontinuation in Cohort 2 was noted, although it did not reach statistically significance (Log Rank p= 0.13). Multivariable Cox regressions in the Caller subgroup, intended to adjust for differences between the two cohorts (i.e., assess for possible confounding), could not be performed due to insufficient sample size.
Discussion
Although the study was limited by sample size and duration of follow-up, the results provide additional information on the relationships between side effects, duration of LARC use, and removal. These conclusions largely support the existing evidence but also provide additional insight into the LARC user and provider experience.
A common belief is that most women experience LARC side effects after insertion. While this study could not determine how many women experienced side effects, it did show that approximately 1 in 5 women called for assistance in managing their side effects. If any of the other 80% who did not call had adverse effects, it is assumed that they were tolerable without medical management or could wait until a scheduled follow-up appointment at 6-8 weeks post-insertion.
Providers commonly perceive that "many" women get their LARC out early due to side effects, 6 although this perception has been challenged in the literature. 7, 8, 9, 10, 11 In this study, only 8% of women discontinued their LARC early, and even fewer (5.5%) discontinued within three months. This suggests that most women do continue their LARC past the first three months, when side effects are most troublesome, contrary to provider perception. It is likely that provider perception is influenced by availability bias, providing more reason for evaluation of real patient outcomes to counteract this perception.
The rate of calls for LARC complaints was not significantly different between cohorts; however, 3 callers discontinued their LARC in Cohort 1, versus 0 in Cohort 2.
While not statistically significant and limited by the number of women who called, there is clinical value in decreasing early LARC removal from 3 to 0. Viewed a different way, 100% of women in Cohort 2 who were counseled using the guideline decided to continue their LARC past 3 months, which provides some evidence to support further evaluation and possible dissemination of the guideline.
Strengths of this study include a diverse sample, complete data, and precise descriptive data due to sampling technique. The conclusions support existing evidence and provide evidence supporting further evaluation of the triage guideline. In addition, the conclusion that only a small proportion of women choose to remove LARC early for any reason, but especially due to side effects, refutes the belief that, for many women, LARC are not a cost-effective option.
This study had limitations. Statistical power was restricted by the small sample size of the subset of callers. As previously discussed, multivariable regression to adjust for between-cohort differences could not be done on the Caller subgroup. Although none of the differences had univariate associations with outcome, the numbers were small. In addition, follow-up data was limited by the short duration of follow-up, dictated by the parameters of the pilot study. Since women often presented for routine follow-up appointments after LARC placement without calling telephone triage, some opportunities for use of the guideline were lost. Revision and evaluation of the guideline for use in pre-& post-insertion and follow-up counseling could provide insight into the efficacy of the guideline in these circumstances. Lastly, political and economic factors may have influenced LARC continuation.
Further research into the efficacy of the guideline is warranted. Future studies can provide larger samples in conjunction with longer follow-up. Qualitative data regarding patient satisfaction and experience with side effect management is important to ensuring that patient autonomy is not lost in the pursuit of high contraceptive efficacy and costeffectiveness.
Conclusion
The trend toward decreased discontinuation of LARC with use of the guideline (although not statistically significant) and the absence of known risks to utilizing the guideline supports dissemination and use of the guideline, with continued evaluation, in women's health, primary care, and pediatric practices to improve LARC use. Use of the guideline could reduce health care costs by reducing patient visits for management of side effects and more effectively utilizing the nursing scope of practice. LARC have the potential to improve the lives of women if the healthcare system is adequately able to support the LARC users for as long as they wish to continue the method. Goal: to effectively manage side effects of long-acting reversible contraceptives (LARC) primarily using telephone triage while promoting patient autonomy. • Schedule appointment  Due to expiration of device (confirmed)?
LARC:
• Determine whether new LARC is desired • Schedule appointment  Due to complaint of side effects?
• See below: complaints of side effects o Patient has complaint of side effects from LARC  Is complaint is a sign of clinical urgency?
• Consult with on-site provider for next step (ED, stat visit)  Is this the first cycle in which patient is reporting side effects of LARC?
• See guideline for specific side effect management  Has the patient tried recommended side effect management strategies?
• If multiple strategies have been unsuccessful for 1 cycle, assess whether patient is amenable to continuing strategies for longer. o If patient insists on removal, schedule removal  Further discussion of management & options to be done at removal appointment by provider  Is patient too emotional to be triaged by telephone?
• Inform patient that she can schedule appointment to further discuss her concerns with provider
Signs of Clinical Urgency
• Currently hospitalized with method-related problem Cramping is usually worst in the first 3 months after IUD insertion and each month will usually subside by day 3 of the menstrual cycle.
1.
Heat and rest, as well as exercise, may help relieve cramping 6, 8 2. Take low-dose ibuprofen or naproxen sodium to help with the cramping 2, 6, 8 Dysmenorrhea is worst for the first few cycles after IUD insertion, especially with the Copper IUD 2, 6 Cramping is an uncommon complaint for implant users but may occur as their cycles adapt to the continuous hormone level 4, 7 .
Mild to moderate dysmenorrhea can be managed with a 3-day course of NSAID therapy 2, 6 .
Patients with persistent dysmenorrhea or new-onset dysmenorrhea >6 months after insertion should be evaluated for pelvic inflammatory disease, ectopic pregnancy, and IUD malposition 6
Long, heavy, or irregular menses (menorrhagia or metorrhagia)
1. Reassure patient that bleeding is often irregular for first 3-6 months of use but improves/stabilizes over time with IUD and implants. Hormonal IUDS and implants often result in amenorrhea over time 4, 6, 8 .
2.
Over-the-counter (RN to consult with provider before recommending):
• Rule out contraindications to NSAID use • Start regimen at onset of bleeding • Ibuprofen 600mg tab TID x 5-7 days OR • Naproxen sodium 220mg tab 2 tabs BID x 5-7 days 2, 3, 4, 6, 7, 8 If unsuccessful x1 cycle:
3. Rx (forward request to provider) one of the following:
• Naproxen sodium 500mg tab 1 tab PO BID x 5-7 days Irregular bleeding with hormonal contraception is considered to be a result of the thick endometrium thinning and developing a dense but fragile capillary network that are prone to incidental bleeding over the first 3-6 months after insertion 2, 4, 7, 8 Reassurance is the primary management strategy as symptoms generally resolve on their own within this time 4, 6, 7 NSAIDs and doxycycline act as prostaglandin synthetase inhibitor to restrict pain and bleeding. If irregular bleeding persists despite management strategies or patient refuses strategies, an appointment for removal should be scheduled to initiate a different contraceptive method 1, 4 New or worsening bleeding after the first 6 months of LARC use warrants further evaluation for other causes 4, 7, 8 
Increased vaginal discharge
Clear or milky vaginal discharge is normal (leukorrhea).
IUD and implants provide no protection against sexually transmitted infections and a barrier method, such as condoms, should be used when there is risk of STI transmission 2, 3, 6, 7, 8 If discharge is malodorous, discolored, or accompanied by itching, pain, nausea/vomiting, new onset bleeding, etc, schedule appointment for screening for vaginal infection/STI 3, 6, 7, 8 Leukorrhea is a normal response to increased progesterone levels with hormonal contraception 7, 8 Changes in vaginal flora and pH are common with IUDs, especially with concurrent irregular bleeding. Decreases in lactobacilli and increases in anaerobic bacteria commonly result in benign but bothersome changes in vaginal discharge 9 Triage for signs of infection and schedule appointment for screening if vaginal or uterine infection is suspected. Infections >3 weeks after IUD insertion date are usually vaginal and related to STI risk, BV, or candidiasis 6, 8 Pain accompanied by fever, discharge at the insertion site, and/or significant swelling and erythema suggests infection or rejection and should be evaluated by a provider in the office 4 
